Interleukin-1 receptor antagonist allele (IL1RN(*)2) associated with nephropathy in diabetes mellitus

被引:14
|
作者
Blakemore, AIF
Cox, A
Gonzalez, AM
Maskill, JK
Hughes, ME
Wilson, RM
Ward, JD
Duff, GW
机构
[1] SHEFFIELD HALLAM UNIV,DIV BIOMED SCI,SHEFFIELD S1 1WB,S YORKSHIRE,ENGLAND
[2] UNIV SHEFFIELD,ROYAL HALLAMSHIRE HOSP,DEPT MED,SECT MOLEC MED,SHEFFIELD S10 2JF,S YORKSHIRE,ENGLAND
[3] ROYAL HALLAMSHIRE HOSP,CTR DIABET,SHEFFIELD S10 2JF,S YORKSHIRE,ENGLAND
关键词
D O I
10.1007/s004390050055
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
We have previously found association between an allele of the interleukin-l (IL-1) receptor antagonist gene (IL1RN) and several inflammatory diseases, where IL-1 has been implicated in the inflammatory mechanism. We have now, therefore, tested the association of this specific allele (IL1RN*2) with complications of diabetes which have an inflammatory tissue component. We have tested the allele frequency of IL1RN*2 in 128 patients with insulin-dependent and 125 with non-insulin-dependent diabetes mellitus (NIDDM). There was a significant association between carriage of IL1RN*2 and diabetic nephropathy (P < 0.0001, P-corrected < 0.0012). The association was significant in both types of diabetes, but the observed increase was highest in NIDDM, rising to double the control levels, It appears that IL1RN*2 is a novel genetic marker of severity of inflammatory complications of diseases rather than a marker of disease susceptibility. If the DNA polymorphism is associated with altered gene function, new therapeutic interventions may be possible.
引用
收藏
页码:369 / 374
页数:6
相关论文
共 50 条
  • [21] Interleukin-1 Receptor Antagonist Gene (IL1RN) Variants Modulate the Cytokine Release Syndrome and Mortality of COVID-19
    Attur, Mukundan
    Petrilli, Christopher
    Adhikari, Samrachana
    Iturrate, Eduardo
    Li, Xiyue
    Tuminello, Stephanie
    Hu, Nan
    Chakravarti, Aravinda
    Beck, David
    Abramson, Steven B.
    JOURNAL OF INFECTIOUS DISEASES, 2024, 229 (06): : 1740 - 1749
  • [22] Association between Interleukin-1 Receptor Antagonist (IL1RN) Variable Number of Tandem Repeats (VNTR) Polymorphism and Pulmonary Tuberculosis
    Hashemi, Mohammad
    Naderi, Mohammad
    Ebrahimi, Mahboubeh
    Amininia, Shadi
    Bahari, Gholamreza
    Taheri, Mohsen
    Eskandari-Nasab, Ebrahim
    Ghavami, Saeid
    IRANIAN JOURNAL OF ALLERGY ASTHMA AND IMMUNOLOGY, 2015, 14 (01) : 55 - 59
  • [23] Polymorphisms in interleukin-1 and interleukin-1 receptor antagonist genes are associated with kidney failure in Korean patients with type 2 diabetes mellitus
    Lee, SH
    Ihm, CG
    Sohn, SD
    Lee, TW
    Kim, MJ
    Koh, G
    Oh, SJ
    Woo, JT
    Kim, SW
    Kim, JW
    Kim, YS
    Lee, BC
    Kim, SD
    Cho, BS
    Lee, HJ
    Chung, JH
    AMERICAN JOURNAL OF NEPHROLOGY, 2004, 24 (04) : 410 - 414
  • [24] Interleukin-1 Receptor Antagonist: A New Therapy for Type 2 Diabetes Mellitus
    Akash, Muhammad Sajid Hamid
    Shen, Qi
    Rehman, Kanwal
    Chen, Shuqing
    JOURNAL OF PHARMACEUTICAL SCIENCES, 2012, 101 (05) : 1647 - 1658
  • [25] Association between the interleukin 1 receptor antagonist (IL1RN) intronic repeat and dysregulated eating behaviour
    Ebstein, Richard
    AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS, 2006, 141B (07) : 720 - 720
  • [26] Further evidence of an association between allele 2 of the interleukin-1 receptor antagonist gene (IL-1RN) polymorphism and ulcerative colitis
    Carter, MJ
    Jones, S
    Mansfield, J
    di Giovine, FS
    Camp, NJ
    Lobo, AJ
    Duff, GW
    GUT, 1998, 42 : A2 - A2
  • [27] Analysis of the expression and potential molecular mechanism of interleukin-1 receptor antagonist (IL1RN) in papillary thyroid cancer via bioinformatics methods
    Zhenyu Xie
    Xin Li
    Yuzhen He
    Song Wu
    Shiyue Wang
    Jianjian Sun
    Yuchen He
    Yu Lun
    Shijie Xin
    Jian Zhang
    BMC Cancer, 20
  • [28] Case report: Novel compound heterozygous IL1RN mutations as the likely cause of a lethal form of deficiency of interleukin-1 receptor antagonist
    Urbaneja, Elena
    Bonet, Nuria
    Solis-Moruno, Manuel
    Mensa-Vilaro, Anna
    de Landazuri, Inaki Ortiz
    Tormo, Marc
    Lara, Rocio
    Plaza, Susana
    Fabregat, Virginia
    Yaguee, Jordi
    Casals, Ferran
    Arostegui, Juan I.
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [29] Analysis of the expression and potential molecular mechanism of interleukin-1 receptor antagonist (IL1RN) in papillary thyroid cancer via bioinformatics methods
    Xie, Zhenyu
    Li, Xin
    He, Yuzhen
    Wu, Song
    Wang, Shiyue
    Sun, Jianjian
    He, Yuchen
    Lun, Yu
    Xin, Shijie
    Zhang, Jian
    BMC CANCER, 2020, 20 (01)
  • [30] INTERLEUKIN-1 (IL-1) AND INTERLEUKIN-1 RECEPTOR ANTAGONIST (IL-1RA)
    CONTI, P
    ANNALES DE MEDECINE INTERNE, 1991, 142 (07): : 521 - 525